APN - Aspen - Completion Of Multiple Strategic Inter - Dependant Transactions

APN - Aspen - Completion Of Multiple Strategic Inter - Dependant Transactions   
                   Between Aspen And The Glaxosmithkline Group ("GSK")          
ASPEN PHARMACARE HOLDINGS LIMITED                                               
(Incorporated in the Republic of South Africa)                                  
Registration number 1985/0002935/06                                             
Share code:  APN                                                                
ISIN:  ZAE000066692                                                             
("Aspen")                                                                       
Completion  of  multiple strategic inter - dependant transactions between  Aspen
and the GlaxoSmithKline Group ("GSK")                                           
Further  to  the  announcement issued on SENS on 12 May 2009,  Aspen  wishes  to
update shareholders on the status of completion of the multiple strategic  inter
- dependant transactions entered into between Aspen and GSK.                    
The conditions precedent to the agreement have been fulfilled.                  
The Completion Date for the transaction will be 30 November 2009.               
Due to regulatory requirements, Aspen and GSK have agreed that-                 
-  the  transaction  in  terms of which Aspen`s wholly-owned  subsidiary,  Aspen
Global, will acquire eight specialist products from GSK will only be implemented
in  respect  of Tanzania, Namibia and Zimbabwe upon approval from the Tanzanian,
Namibian and Zimbabwean authorities, respectively.                              
-  the Sub-Saharan collaboration transaction will only be implemented in respect
of Tanzania, Namibia and Zimbabwe upon approval from the Tanzanian, Namibian and
Zimbabwean authorities, respectively.                                           
The  portion  of the purchase consideration payable to GSK for these territories
is  negligible  and  consequently there will be no adjustment  to  the  purchase
consideration as communicated to shareholders in the SENS announcement issued on
12  May  2009. It is expected that the consideration shares, comprising of  68.5
million ordinary shares in the share capital of Aspen, will be listed and issued
to GSK on 30 November 2009.                                                     
3 November 2009                                                                 
Sponsor:                                                                        
Investec Bank Limited                                                           
Date: 03/11/2009 10:49:01 Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.